Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients

NCT02287428 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02287428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02287428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 30, 2014
Completion date
February 29, 2028
Enrollment
56 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma